Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoglobulin and rituximab for chronic antibody-mediated rejection after kidney transplantation
2010-023746-67Phase 2Completed
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in kidney allograft rejection comparing Human immunoglobulin G + rituximab with Placebo control (2 arms). Primary endpoint: Change in estimated glomerular filtration rate at 1 year. Started Feb 2011; status: completed.
02
Drugs
rituximabIgPro10
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2010-023746-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023746-67.